Clinical trials: in Algeria
Diabetes, Diabetes Mellitus, Type 2
A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin
This trial is conducted in Africa, Europe and the United States of America (USA). The aim of the trial is to compare the difference in change in glycosylated haemoglobin (HbA1c) between insulin degludec/insulin aspart (IDegAsp)…
- Trial name
- NCT01713530
- Testing
- insulin degludec/insulin aspart, insulin degludec, insulin aspart
- Where
- 51 sites in United States, Algeria and 3 more
- Volunteers
- 274 people
- Sponsor
- Novo Nordisk A/S
Lymphoma, Large B-Cell, Diffuse
A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma
This multicenter, randomized, open label parallel-group study will evaluate the efficacy and safety of subcutaneous versus intravenous MabThera/Rituxan (rituximab) in combination with CHOP chemotherapy in patients with previously…
- Trial name
- NCT01649856
- Testing
- CHOP, rituximab [MabThera/Rituxan]
- Where
- 186 sites in Algeria, Argentina and 25 more
- Volunteers
- 572 people
- Sponsor
- Hoffmann-La Roche
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes
This trial is conducted in Africa and Asia. The aim of the trial is to investigate the efficacy and safety of liraglutide versus sulphonylurea (SU) both in combination with metformin during Ramadan in subjects with type 2…
- Trial name
- LIRA-Ramadan™ (NCT01917656)
- Testing
- liraglutide, metformin, sulphonylurea
- Where
- 41 sites in Algeria, India and 5 more
- Volunteers
- 343 people
- Sponsor
- Novo Nordisk A/S
Gastrointestinal Stromal Tumors
Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST)
GISTs are the most common mesenchymal tumors of the gastrointestinal tract. Approximately 95% of GISTs are positive for KIT (CD117)-the receptor for stem cell factor (SCF).
- Trial name
- INV555 (NCT01172548)
- Testing
- imatinib mesylate
- Where
- 29 sites in Algeria, Egypt and 10 more
- Volunteers
- 132 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes, Diabetes Mellitus, Type 2
A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily
This trial is conducted globally. The aim of the trial is to compare efficacy of insulin degludec/insulin aspart (IDegAsp) twice daily (BID) + insulin aspart (IAsp) once daily (OD) versus basal bolus with insulin degludec (IDeg)…
- Trial name
- BOOST® (NCT01814137)
- Testing
- insulin degludec/insulin aspart, insulin degludec, insulin aspart
- Where
- 40 sites in United States, Algeria and 3 more
- Volunteers
- 40 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Children With Type 1 Diabetes
This study is conducted in Africa. The aim of this non-interventional study is to evaluate the current status of diabetes management, complications and psychosocial aspects for children with type 1 diabetes in Algeria.
- Trial name
- Diabcare (NCT01435642)
- Testing
- No treatment given
- Where
- Algeria
- Volunteers
- 349 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Observational Study on the Effect of NovoMix® 30, Levemir® or NovoRapid® (Alone or Combined) in Type 2 Diabetics Previously Treated With Anti-diabetic Medication
This study is conducted in Africa, Asia, South America and Europe. The aim of this observational study is to document the experience with the study insulins when used in routine clinical practice.
- Trial name
- A1chieve® (NCT00869908)
- Testing
- insulin aspart, insulin detemir, biphasic insulin aspart
- Where
- 22 sites in Algeria, Argentina and 20 more
- Volunteers
- 66,726 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
Diabetes Attitudes Wishes and Needs
The study is conducted in Africa, Asia, Europe, Japan, North America and South America. The multinational surveys will explore the experiences and unmet needs of people with diabetes, as well as those of family members of people…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Relatives to/Carers of Patients
- Trial name
- DAWN2 (NCT01507116)
- Testing
- No treatment given
- Where
- 17 sites in United States, Algeria and 15 more
- Volunteers
- 8,985 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Effect of Different Insulin Administrations, All in Combination With Metformin, on Glycaemic Control in Subjects With Type 2 Diabetes Inadequately Controlled by Oral Anti-diabetic Drugs
This trial is conducted in Africa. The aim of this clinical trial is to investigate the effect of 50 weeks of treatment with different intensified insulin administrations (all in combination with a fixed dose of metformin) on…
- Trial name
- NCT01068652
- Testing
- insulin detemir, insulin aspart, biphasic insulin aspart 30
- Where
- 19 sites in Algeria, Egypt and 3 more
- Volunteers
- 403 people
- Sponsor
- Novo Nordisk A/S
Congenital Bleeding Disorder, Haemophilia A With Inhibitors
Observational Registry of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors
This study was conducted in Africa, Europe, the Middle-East and South America. The primary objective of this registry was to observe the use of single dose and multi-dose use of activated recombinant human factor VII and to…
- Conditions
- Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
- Trial name
- ONE (NCT00703911)
- Testing
- eptacog alfa (activated)
- Where
- 16 sites in Algeria, Austria and 14 more
- Volunteers
- 102 people
- Sponsor
- Novo Nordisk A/S
Asthma
Multicentric, Transversal, Descriptive, Epidemiological Study on the Management of Asthma in Asthmatic Middle East Adult Population
Descriptive study on the management of asthma in asthmatic Middle East adult population : Algeria,Egypt, Irak,Iran, Jordan, Koweit, Lebanon, Qatar,Saudi,Tunisia, UAE
- Trial name
- ESMAA (NCT02153411)
- Where
- 98 sites in Algeria, Egypt and 9 more
- Volunteers
- 7,294 people
- Sponsor
- AstraZeneca
Hepatitis C, Chronic
An Observational Study on The Prediction of Adverse Events in Patients With Chronic Hepatitis C Receiving a Long-Acting Interferon Plus Ribavirin (GUARD-C)
This observational study will assess factors leading to dose reductions/treatment discontinuations and the effect on sustained virological response in patients with chronic hepatitis C receiving a long-acting interferon (e.g.
- Trial name
- NCT01344889
- Where
- 260 sites in Albania, Algeria and 23 more
- Volunteers
- 4,459 people
- Sponsor
- Hoffmann-La Roche
Multiple Myeloma
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
The primary objective of this observational study is to document and describe current treatment regimens and disease progression of patients with Multiple Myeloma (MMY).
- Trial name
- NCT01241396
- Testing
- Any MMY treatment
- Where
- 159 sites in Algeria, Austria and 19 more
- Volunteers
- 2,396 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Chronic Myeloid Leukemia
Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients
This study will further investigate the safety and efficacy of nilotinib in newly diagnosed chronic myeloid leukemia patients in the chronic phase
- Trial name
- ENESTxtnd (NCT01254188)
- Testing
- Nilotinib
- Where
- 100 sites in Algeria, Argentina and 17 more
- Volunteers
- 421 people
- Sponsor
- Novartis Pharmaceuticals
Female Contraception
Descriptive, Prospective, Non-interventional Study (NIS) to Describe Mirena and Amenorrhea Related Acceptability in Contraception Indication in Medical Practice
MARILIA is a prospective, non-interventional, multicenter study. The purpose of this study is to describe the acceptability of Amenorrhea in contraception indication of Mirena users during one year follow up in medical practice.
- Trial name
- MARILIA (NCT01833793)
- Testing
- Levonorgestrel IUD (Mirena, BAY86-5028)
- Where
- Algeria
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Bayer
Hypertension
Impact of Ramadan on Achieving Joint National Committee (JNC) 7 Treatment Goals in CV Risk Patients
This is an out-patient based prospective, multi-centre, observational post-marketing surveillance study amongst internists and cardiologists.
- Trial name
- NCT01853839
- Where
- 132 sites in Algeria, Egypt and 3 more
- Volunteers
- 1,674 people
- Sponsor
- Boehringer Ingelheim
Nasopharyngeal Neoplasms, Carcinoma
Docetaxel in Combination With Cisplatin-5-fluorouracil for the Induction Treatment of Nasopharyngeal Carcinoma in Children and Adolescents
The primary objective is to estimate the Complete Response rate of docetaxel to the combination of cisplatin-5-fluorouracil (TCF) compared to cisplatin-5-fluorouracil (CF) in the Induction treatment of Nasopharyngeal Carcinoma…
- Trial name
- NCT00565448
- Testing
- docetaxel, cisplatin, 5-fluorouracil
- Where
- 26 sites in Algeria, Brazil and 12 more
- Volunteers
- 75 people
- Sponsor
- Sanofi
Myocardial Infarction, Segment Elevation Myocardial Infarction (STEMI)
A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)
The aim of this study is to determine whether initiation of ticagrelor as early as in the ambulance setting leads to a rapid reperfusion of the infarct-related artery therefore facilitating the Percutaneous Coronary Intervention…
- Trial name
- ATLANTIC (NCT01347580)
- Testing
- Ticagrelor
- Where
- 96 sites in Algeria, Australia and 11 more
- Volunteers
- 1,875 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Efficacy and Safety Comparison of Metformin/Glimepiride Combination Versus Each Compound Alone in New Diagnosed Type 2 Diabetes Patients
Primary Objective: To demonstrate the superiority of glimepiride and metformin free combination in comparison to glimepiride or metformin alone in terms of Hb1Ac reduction during a 24-week treatment period in patients with type 2…
- Trial name
- RECOMMEND (NCT01459809)
- Testing
- GLIMEPIRIDE, METFORMIN
- Where
- 55 sites in Algeria, Colombia and 12 more
- Volunteers
- 538 people
- Sponsor
- Sanofi
Congenital Bleeding Disorder, Glanzmann's Disease
Observational Registry of the Treatment of Glanzmann's Thrombasthenia
This observational registry is conducted in Europe, Asia, Africa and the United States of America (USA). The purpose of the registry is to evaluate the efficacy and safety of activated recombinant human factor VII (rFVIIa) during…
- Trial name
- NCT01476423
- Testing
- activated recombinant human factor VII
- Where
- 15 sites in United States, Algeria and 13 more
- Volunteers
- 218 people
- Sponsor
- Novo Nordisk A/S